FrancophonIA/ELRC3.0 huggingface dataset:
English: Type I glass vial closed with bromobutyl rubber stopper and aluminium seal containing 16.7 mL of solution.
Slovenian: Viala iz stekla tipa I, zaprta z zamaškom iz brombutilne gume in aluminijasto zaporo; viala vsebuje 16,7 ml raztopine.
English: • some patients have also reported feeling confused after taking Noxafil.
Slovenian: • nekateri bolniki so po jemanju zdravila Noxafil poročali tudi o občutku zmedenosti.
English: You may feel dizzy, sleepy, or have blurred vision while taking Noxafil, which may affect your ability to drive or use tools or machines.
Slovenian: Med uporabo zdravila Noxafil ste lahko omotični, zaspani ali imate zamegljen vid, kar lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
English: Patients who have severe diarrhoea or vomiting should be monitored closely for breakthrough fungal infections.
Slovenian: Bolnike, ki imajo hudo drisko ali bruhajo, je treba skrbno spremljati glede prebijajočih (breakthrough) glivnih okužb.
English: Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion, and paralytic ileus.
Slovenian: Sočasna uporaba azolskih antimikotikov, vključno s posakonazolom, in vinkristina je bila povezana z nevrotoksičnostjo in drugimi resnimi neželenimi učinki, vključno z epileptičnimi napadi, periferno nevropatijo, sindromom neustreznega izločanja antidiuretskega hormona in paralitičnim ileusom.
English: In a nonclinical study using intravenous administration of posaconazole in very young dogs (dosed from 2-8 weeks of age) an increase in the incidence of brain ventricle enlargement was observed in treated animals as compared with concurrent control animals.
Slovenian: V predklinični študiji intravenske uporabe posakonazola pri zelo mladih psih (ki so zdravilo prejemali v starosti od 2 do 8 tednov) so pri živalih, ki so dobivale zdravilo, opazili večjo pojavnost povečanja možganskih prekatov kot pri sočasnih kontrolnih živalih.
English: Alternatively, if recommended by your doctor, you may take 400 mg (two 5 mL spoonfuls) twice a day provided that you are able to take both doses during or after food or a nutritional drink.
Slovenian: Druga možnost je, če vam tako svetuje zdravnik, da zaužijete po 400 mg (dve polni 5 ml žlički) suspenzije dvakrat na dan, če imate možnost, da ta dva odmerka vzamete med ali takoj po jedi ali zaužitju prehranskega dopolnila v obliki napitka.
English: • Congenital or acquired QTc prolongation
Slovenian: • kongenitalno ali pridobljeno podaljšanje intervala QTc,
English: Patients with a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events.
Slovenian: Bolniki z majhno telesno maso (< 60 kg) imajo večjo verjetnost za povečane koncentracije posakonazola v plazmi in jih je treba skrbno spremljati glede neželenih učinkov.
English: What Noxafil looks like and contents of the pack
Slovenian: Izgled zdravila Noxafil in vsebina pakiranja
English: Posaconazole, after administration of the tablet, has a mean apparent volume of distribution of 394 L (42 %), ranging between 294-583 L among the studies in healthy volunteers.
Slovenian: Po uporabi tablet je povprečni navidezni volumen porazdelitve posakonazola 394 l (42 %) in v študijah pri zdravih prostovoljcih sega od 294 do 583 l.
English: Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole concentrate for solution for infusion when given as antifungal prophylaxis (Study 5520).
Slovenian: Bolnike so vključili v neprimerjalno preskušanje farmakokinetike in varnosti posakonazola v koncentratu za raztopino za infundiranje, uporabljenega za antimikotično profilakso (študija 5520).
English: Patients, in particular those receiving posaconazole after HSCT, who have a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events.
Slovenian: Bolniki, zlasti tisti, ki prejemajo posakonazol po presaditvi hematopoetskih celic in imajo majhno telesno maso (< 60 kg), imajo večjo verjetnost za povečane koncentracije posakonazola v plazmi in jih je treba skrbno spremljati glede neželenih učinkov.
English: In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200 mg once daily increased ciclosporin concentrations requiring dose reductions.
Slovenian: Pri bolnikih s presajenim srcem, ki prejemajo stabilne odmerke ciklosporina, je peroralna suspenzija posakonazola v odmerku 200 mg enkrat na dan povečala koncentracijo ciklosporina, tako da je bilo potrebno zmanjšanje njegovega odmerka.
English: Noxafil concentrate for solution for infusion requires dilution (see section 6.6) prior to administration.
Slovenian: Zdravilo Noxafil koncentrat za raztopino za infundiranje je treba pred uporabo razredčiti (glejte poglavje 6.6).
English: As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents.
Slovenian: Zaviralci proteaze HIV so substrati CYP3A4, zato se pričakuje, da bo posakonazol povečal plazemsko koncentracijo teh protiretrovirusnih zdravil.
English: Serum creatinine levels should be closely monitored in these patients (see section 4.4).
Slovenian: Pri teh bolnikih je treba natančno kontrolirati koncentracijo kreatinina v serumu (glejte poglavje 4.4).
English: In healthy volunteers under fasting conditions, dividing the total daily dose (800 mg) into 200 mg four times daily compared to 400 mg twice daily, was shown to increase posaconazole exposure by 2.6-fold.
Slovenian: Pri zdravih prostovoljcih na tešče so pokazali, da razdelitev celotnega dnevnega odmerka (800 mg) na 200 mg štirikrat na dan v primerjavi s 400 mg dvakrat na dan poveča izpostavljenost posakonazolu za 2,6-krat.
English: Thromboembolic events have been identified as a potential risk for posaconazole intravenous concentrate for solution for infusion but were not observed in the clinical studies.
Slovenian: Obstaja potencialno tveganje tromboemboličnih dogodkov pri uporabi posakonazola v obliki intravenskega koncentrata za raztopino za infundiranje, vendar ga v kliničnih študijah niso opazili.
English: • astemizole (used to treat allergies)
Slovenian: • astemizol (za zdravljenje alergij)
English: Noxafil is also available for oral administration (Noxafil 100 mg gastro-resistant tablets and 40 mg/mL oral suspension).
Slovenian: Zdravilo Noxafil je na voljo tudi za peroralno uporabo (Noxafil 100 mg gastrorezistentne tablete in 40 mg/ml peroralna suspenzija).
English: • Glipizide or other “sulfonylureas” (used to treat high blood sugar).
Slovenian: • glipizid ali druge sulfonilsečnine (uporabljajo se za zdravljenje zvišanega sladkorja v krvi).
English: Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders.
Slovenian: Med osemnajstimi bolniki, ki niso prenašali amfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.
English: When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose).
Slovenian: Ob uvedbi zdravljenja s posakonazolom je treba bolnikom, ki že prejemajo takrolimus, odmerek takrolimusa zmanjšati (npr. na približno tretjino trenutnega odmerka).
English: Investigations Uncommon:
Slovenian: Preiskave Občasni:
English: Since certain adverse reactions (e.g. dizziness, somnolence, etc.) have been reported with posaconazole use, which potentially may affect driving/operating machinery, caution needs to be used.
Slovenian: Ker so med uporabo posakonazola poročali o nekaterih neželenih učinkih (npr. omotici, zaspanosti, itd.), ki lahko poslabšajo sposobnost vožnje in upravljanja s stroji, je potrebna previdnost.
English: 200 mg three times daily
Slovenian: 200 mg trikrat na dan
English: When administered through a peripheral venous catheter, the infusion should be administered over approximately 30 minutes.
Slovenian: Če je zdravilo uporabljeno po perifernem venskem katetru, mora infundiranje trajati približno 30 minut.
English: Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine)
Slovenian: Zaviralci kalcijevih kanalčkov, ki se presnovijo s CYP3A4 (npr. diltiazem, verapamil, nifedipin, nizoldipin)
English: HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and atorvastatin)
Slovenian: Zaviralci reduktaze HMG-CoA, ki se presnovijo s CYP3A4 (npr. simvastatin, lovastatin in atorvastatin)
English: Noxafil gastro-resistant tablets are yellow-coated and capsule-shaped, debossed “100” on one side packaged in a blister in cartons of 24 (2x12) or 96 (8x12) tablets.
Slovenian: Noxafil gastrorezistentne tablete so rumene, obložene tablete v obliki kapsule ter imajo na eni strani vtisnjeno oznako "100"; pakirane so v pretisnih omotih v škatlah, ki vsebujejo po 24 (2 x 12) ali 96 (8 x 12) tablet.
English: For patients with AML or MDS, prophylaxis with Noxafil should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm
Slovenian: Pri bolnikih z AML ali MDS je treba profilakso z zdravilom Noxafil začeti več dni pred pričakovanim pojavom nevtropenije in naj traja še 7 dni po zvečanju števila nevtrofilcev nad 500 celic/mm
English: Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations.
Slovenian: Sočasna uporaba fosamprenavirja in posakonazola lahko zmanjša koncentracijo posakonazola v plazmi.
English: • tacrolimus and sirolimus (used during or after transplant surgery)
Slovenian: • takrolimus in sirolimus (uporabljata se med ali po presaditvah),
English: When administered through a peripheral venous catheter, the infusion should be administered over approximately 30 minutes to reduce the likelihood of infusion site reactions (see section 4.8).
Slovenian: Če je zdravilo dano po perifernem venskem katetru, mora infundiranje trajati približno 30 minut, da se zmanjša verjetnost reakcij na mestu infundiranja (glejte poglavje 4.8).
English: Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
Slovenian: Dokazano je, da posakonazol in vitro deluje proti naslednjim mikroorganizmom: vrsti Aspergillus (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), vrsti Candida (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, in vrstam Fusarium, Rhizomucor, Mucor in Rhizopus.
English: • ciclosporin (used during or after transplant surgery)
Slovenian: • ciklosporin (uporablja se med ali po presaditvah),
English: If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended.
Slovenian: V primeru sočasne uporabe je priporočljivo skrbno spremljanje celotne krvne slike in neželenih učinkov, povezanih s povečano koncentracijo rifabutina (npr. uveitisa).
English: The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient.
Slovenian: Učinek sočasne uporabe posakonazola na plazemske koncentracije substratov CYP3A4 se lahko razlikuje tudi pri posameznem bolniku.
English: Posaconazole tablets are absorbed with a median Tmax of 4 to 5 hours and exhibits dose proportional pharmacokinetics after single and multiple dosing up to 300 mg.
Slovenian: Tablete posakonazola se absorbirajo s srednjo vrednostjo tmax od 4 do 5 ur in imajo po enkratnem in večkratnih odmerkih do 300 mg odmerku sorazmerno farmakokinetiko.
English: The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period.
Slovenian: Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanih oziroma verjetnih invazivnih glivnih okužb, ki jih je ugotavljala neodvisna skupina zunanjih strokovnjakov na slep način med obdobjem zdravljenja.
English: • rifabutin (used to treat certain infections)
Slovenian: • rifabutin (uporablja se za zdravljenje določenih okužb),
English: The primary efficacy endpoint was the incidence of proven/probable IFIs at 16 weeks post-randomisation as determined by an independent, blinded external expert panel.
Slovenian: Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanih oziroma verjetnih invazivnih glivnih okužb 16 tednov po randomizaciji, ki jih je ugotavljala neodvisna skupina zunanjih strokovnjakov na slep način.
English: Noxafil contains glucose
Slovenian: Zdravilo Noxafil vsebuje glukozo
English: The most frequently reported adverse reaction (>25 %) with an onset during the posaconazole intravenous phase of dosing with 300 mg once daily was diarrhoea (32 %).
Slovenian: Najpogosteje poročani neželeni učinek (> 25 %), ki se je pojavil med intravensko fazo uporabe posakonazola v odmerku 300 mg enkrat na dan, je bila driska (32 %).
English: Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose.
Slovenian: Pri zdravih prostovoljcih je bilo opravljenih več študij medsebojnega delovanja posakonazola z drugimi zdravili, pri katerih je bila izpostavljenost posakonazolu večja kot pri bolnikih, ki so prejemali enak odmerek.
English: If you develop severe diarrhoea or vomiting (being sick) while taking Noxafil, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly.
Slovenian: Če se med jemanjem zdravila Noxafil pojavita huda driska ali bruhanje (slabost), se takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, kajti lahko preprečita pravilno delovanje zdravila.
English: Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates) Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated.
Slovenian: Terfenadin, astemizol, cisaprid, pimozid, halofantrin in kinidin (substrati CYP3A4) Sočasna uporaba posakonazola in terfenadina, astemizola, cisaprida, pimozida, halofantrina ali kinidina je kontraindicirana.
English: The most common adverse reaction (>1 %) leading to discontinuation of posaconazole concentrate for solution for infusion 300 mg once daily was AML (1 %).
Slovenian: Najpogostejši neželeni učinek (> 1 %), ki je povzročil prekinitev uporabe posakonazola v koncentratu za raztopino za infundiranje v odmerku 300 mg enkrat na dan, je bila AML (1 %).
English: Excipient with known effect: This medicinal product contains approximately 1.75 g of glucose per 5 mL of suspension.
Slovenian: Pomožna snov z znanim učinkom: To zdravilo vsebuje približno 1,75 g glukoze v 5 ml suspenzije.
English: Posaconazole does not have any major circulating metabolites and its concentrations are unlikely to be altered by inhibitors of CYP450 enzymes.
Slovenian: Posakonazol v obtoku nima nobenega glavnega presnovka in ni verjetno, da bi zaviralci encimov CYP450 vplivali na njegovo koncentracijo.
English: Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below.
Slovenian: Sočasna uporaba posakonazola in substratov CYP3A4 lahko zelo poveča izpostavljenost tem substratom, kot kažejo spodaj opisani učinki na takrolimus, sirolimus, atazanavir in midazolam.
English: The study treated 155 (65 %) subjects with AML or MDS, and 82 (35 %) subjects with HSCT, as the primary diseases at study entry.
Slovenian: Primarni razlog zdravljenja v študiji sta bila ob vstopu v študijo AML ali MDS pri 155 (65 %) preiskovancih in HSCT pri 82 (35 %) preiskovancih.
English: The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole.
Slovenian: Zdravljenje s posakonazolom je trajalo povprečno 80 dni in s flukonazolom 77 dni.
English: Following a single dose administration of 300 mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC0-72 hours and Cmax were higher compared to administration under fasted condition (51 % and 16 % for AUC0-72 hours and Cmax respectively).
Slovenian: Po enkratnem odmerku 300 mg posakonazola v tabletah po zelo mastnem obroku sta bili pri zdravih prostovoljcih AUC0-72 ur in Cmax večji kot po uporabi na tešče (AUC0-72 ur 51 % in Cmax 16 %).
English: adrenal insufficiency, blood gonadotropin decreased pseudoaldosteronism
Slovenian: insuficienca nadledvične žleze, znižana raven gonadotropinov v krvi psevdoaldosteronizem
English: Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients (see sections 4.2 and 5.2).
Slovenian: Pri bolnikih z okvaro jeter je treba posakonazol uporabljati previdno, ker je kliničnih izkušenj malo in ker obstaja možnost, da je koncentracija posakonazola v plazmi pri teh bolnikih višja (glejte poglavji 4.2 in 5.2).
English: The AUC of posaconazole is: 4 times greater when administered with a highfat meal (~ 50 grams fat) and about 2.6 times greater when administered during a non-fat meal or nutritional supplement (14 grams fat) relative to the fasted state (see sections 4.2 and 4.5).
Slovenian: Vrednost AUC za posakonazol je 4-krat večja, če ga bolnik zaužije skupaj z zelo mastnim obrokom (~ 50 gramov maščobe) in približno 2,6-krat večja pri zaužitju z nemastnim obrokom ali s prehranskim dodatkom (14 gramov maščobe) v primerjavi s stanjem na tešče (glejte poglavji 4.2 in 4.5).
English: During clinical trials, patients who received posaconazole oral suspension doses up to 1,600 mg/day experienced no different adverse reactions from those reported with patients at the lower doses.
Slovenian: Med kliničnimi preskušanji niso bili neželeni učinki pri bolnikih, ki so dobili peroralno suspenzijo posakonazola v odmerkih do 1.600 mg/dan, nič drugačni od neželenih učinkov, o katerih so poročali pri bolnikih, ki so dobivali manjše odmerke.
English: No dose adjustment is recommended for patients with mild to severe hepatic impairment but caution is advised due to the potential for higher plasma exposure.
Slovenian: Bolnikom z blago do hudo okvaro jeter odmerka sicer ni treba prilagoditi, a je zaradi možne večje plazemske izpostavljenosti priporočljiva previdnost.
English: However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended.
Slovenian: Ker pa se posakonazol skozi ledvice ne izloča v pomembni meri, ni pričakovati, da bi huda okvara ledvic vplivala na farmakokinetiko posakonazola; prilagajanje odmerka tako ni potrebno.
English: Noxafil concentrate for solution for infusion will be diluted to the correct concentration by your pharmacist or nurse.
Slovenian: Zdravilo Noxafil koncentrat za raztopino za infundiranje bosta farmacevt ali medicinska sestra razredčila na ustrezno koncentracijo.
English: Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole).
Slovenian: Sočasni uporabi posakonazola in rifabutina se je treba izogibati, razen če korist za bolnika odtehta tveganje (glejte zgoraj za učinke rifabutina na plazemsko koncentracijo posakonazola).
English: Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4.
Slovenian: Posakonazol lahko bistveno poveča plazemsko koncentracijo zaviralcev reduktaze HMG-CoA, ki se presnovijo s CYP3A4.
English: Following administration of 300 mg posaconazole concentrate for solution for infusion over 90 minutes, mean peak plasma concentration at the end of infusion was 3280 ng/mL (74 % CV).
Slovenian: Po uporabi 300 mg posakonazola v koncentratu za raztopino za infundiranje v 90 minutah je bila povprečna največja koncentracija na koncu infundiranja 3.280 ng/ml (74 % KV).
English: If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse reactions, plasma concentrations of the CYP3A4 substrate and/or adverse reactions should be closely monitored and the dose adjusted as needed.
Slovenian: Med sočasno uporabo posakonazola in peroralnih substratov CYP3A4, pri katerih lahko povečanje plazemske koncentracije spremljajo nesprejemljivi neželeni učinki, je treba skrbno spremljati plazemske koncentracije substrata CYP3A4 in/ali neželene učinke in po potrebi prilagoditi odmerek zdravila.
English: Due to the variability in exposure, patients with severe renal impairment should be monitored closely for breakthrough fungal infections (see section 4.2).
Slovenian: Zaradi variabilne izpostavljenosti je treba bolnike s hudo okvaro ledvic skrbno spremljati glede prebijajočih glivnih okužb (glejte poglavje 4.2).
English: • patients who have a weak immune system due to having chemotherapy for “acute myelogenous leukemia” (AML) or “myelodysplastic syndromes” (MDS)
Slovenian: • pri bolnikih z oslabljenim imunskim sistemom zaradi kemoterapije, potrebne za zdravljenje akutne mieloične levkemije (AML) ali mielodisplastičnih sindromov (MDS);
English: Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Slovenian: Rifabutin (300 mg enkrat na dan) je zmanjšal Cmax (največjo plazemsko koncentracijo) posakonazola na 57 %, AUC posakonazola (površino pod krivuljo plazemske koncentracije v odvisnosti od časa) pa na 51 %.
English: Treatment of azole-susceptible Oropharyngeal Candidiasis (OPC) A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azolesusceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline).
Slovenian: Zdravljenje orofaringealne kandidoze, občutljive na azole Randomizirana, s "slepim ocenjevalcem" kontrolirana študija je bila opravljena pri bolnikih, okuženih z virusom HIV, ki so imeli na azole občutljivo orofaringealno kandidozo (pri večini bolnikov v tej študiji so na začetku študije izolirali C. albicans).
English: Cav quartile analyses of pivotal patient studies with posaconazole tablet and oral suspension Posaconazole tablet
Slovenian: Analiza kvartilov Cav ključnih študij pri bolnikih z uporabo tablet in peroralne suspenzije posakonazola
English: All drug interactions with posaconazole oral suspension, except for those that affect the absorption of posaconazole (via gastric pH and motility) are considered relevant to posaconazole concentrate for solution for infusion as well.
Slovenian: Vsa medsebojna delovanja s posakonazolom v peroralni suspenziji razen tistih, ki vplivajo na absorpcijo posakonazola (zaradi pH v želodcu ali motilitete želodca), so pomembna tudi za posakonazol v koncentratu za raztopino za infundiranje.